Pages that link to "Q38392884"

The following pages link to Glucagon--Early breakthroughs and recent discoveries (Q38392884):

Displaying 24 items.

• Glucagon and heart in type 2 diabetes: new perspectives (Q26738580) (← links)
• Extra-helical binding site of a glucagon receptor antagonist (Q27704695) (← links)
• Multifaceted interplay among mediators and regulators of intestinal glucose absorption: potential impacts on diabetes research and treatment (Q28086792) (← links)
• Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism (Q35928257) (← links)
• The Mechanism Research of Qishen Yiqi Formula by Module-Network Analysis (Q36031974) (← links)
• Glucosensing in the gastrointestinal tract: Impact on glucose metabolism (Q36902266) (← links)
• Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis (Q37239290) (← links)
• Evolving function and potential of pancreatic alpha cells (Q38676911) (← links)
• Glucagon actions on the kidney revisited: possible role in potassium homeostasis. (Q38838119) (← links)
• Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes (Q40557047) (← links)
• Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice (Q46212121) (← links)
• The role of glucagon in weight loss-mediated metabolic improvement: a systematic review and meta-analysis (Q47176353) (← links)
• Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. (Q47566343) (← links)
• The Three Ds of Transcription Activation by Glucagon: Direct, Delayed, and Dynamic. (Q47595219) (← links)
• Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes (Q47625288) (← links)
• Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial (Q57412763) (← links)
• Glucagon Receptor Signaling and Lipid Metabolism (Q64094048) (← links)
• Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin (Q64095605) (← links)
• Intra-islet glucagon signaling is critical for maintaining glucose homeostasis. (Q64886000) (← links)
• An overview of glucagon research (Q89298995) (← links)
• Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy (Q90221531) (← links)
• Clarithromycin and Glipizide Drug-drug Interaction Leading to Refractory Hypoglycemia (Q92512892) (← links)
• Glucagonoma: From skin lesions to the neuroendocrine component (Review) (Q99240812) (← links)
• Roles of Noncoding RNAs in Islet Biology (Q99561822) (← links)